Yazar "Karabulut, Senem" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Clinical Significance of Serum Insulin-Like Growth Factor-1 (Igf-1) and Insulinlike Growth Binding Protein-3 (Igfbp-3) in Patients With Gastric Cancer(CARBONE EDITORE, VIA QUINTINO SELLA, 68, PALERMO 90139, ITALY, 2018) Bademler, Süleyman; Sarı, Murat; Üçüncü, Muhammed Zübeyr; Serilmez, Murat; Karabulut, SenemIntroduction: Early diagnosis reduces mortality in gastric adenocarcinoma (GC). However, there are no markers that can be used to allow early diagnosis. The aim of the present study was to investigate clinical utility of insulin-like growth factor-1 (IGF-1) and insulin-like growth-binding protein-3 (IGFBP-3) in the diagnosis of GC. Materials and methods: Hundred and fifteen patients with histopathologically confirmed diagnosis of GC and 53 age- and sex-matched healthy controls were included in our study at Istanbul University Institute of Oncology. Serum IGF-1 and IGFBP-3 levels were determined using enzyme-linked immunosorbent assay (ELISA). Results: The mean age of the patients was 61 (range: 32-89) years. At the end of the median 11-month follow-up period, 75% (n=86) of the patients died. Serum IGF-1 and IGFBP-3 levels were significantly lower in the patient group than those in the control group (p=0.001). The sensitivity and specificity for IGF-1 were found to be 62.61% and 68.52%, respectively. The sensitivity and specificity for IGFBP-3 were found to be 73.91% and 62.96%, respectively. Serum IGFBP-3 levels were significantly higher in younger patients compared to those in older patients (p=0.009). The median survival was 14±3.3 months (95% CI=7.6- 20.4). 3-year survival rate was 25.6% (95% CI=15.4-35.8). Large T status, high N status and metastasis were found to have a prognostic role on survival (p=0.05, p=0.05, and p=0.003, respectively). Serum IGF-1 and IGFBP-3 concentrations had no prognostic role on survival (p=0.72, p=0.41, respectively). Conclusion: In our study, we showed that serum IGF-1 and IGFBP-3 levels could be used for early diagnosis of GC. We found that these two biomarkers have good sensitivity and specificity in clinical practice.Öğe Clinical Significance of Serum Membrane-Bound Mucin-2 Levels in Breast Cancer(MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, 2019) Bademler, Süleyman; Zırtıloğlu, Alişan; Sarı, Murat; Üçüncü, Muhammed Zübeyr; Doğru, Elif Bilgin; Karabulut, SenemThis study was conducted to investigate the serum levels of membrane-bound mucin 2 (MUC2) in breast cancer (BC) patients and the relationship with tumour progression and known prognostic parameters. We enrolled 127 female patients with histopathologically diagnosed BC who did not receive chemotherapy (CT) or radiotherapy. Serum MUC2 levels were measured by the enzyme-linked immunosorbent assay (ELISA) method and compared with those of 40 age and sex-matched healthy controls. Median age of diagnosis was 50 (range: 26-78). Twenty-eight (22%) patients were metastatic and the most frequent site of metastasis was bone (n = 17, 61%). The median serum MUC2 level of BC patients was significantly higher than that of the controls (198 vs. 54 ng/mL, p < 0.001). There was no significant difference between patients and controls according to known disease-related clinicopathological or laboratory parameters (p > 0.05). Serum MUC2 levels were not associated with survival (p = 0.65). Although serum MUC2 levels might have a diagnostic role, their predictive and prognostic role in survival in BC patients was not detected. Serum levels of MUC2 should be investigated for diagnostic or screening purposes on a larger scale.Öğe CLINICAL UTILITY OF TENSIN 2 LEVELS AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN BREAST CANCER(Carbone Editore, 2021) Serin, Kursat Rahmi; Ucuncu, Zubeyr; Temel, M. Kemal; Bademler, Suleyman; Soydinc, Hilal Oguz; Karanlik, Hasan; Karabulut, SenemBackground: To discuss the diagnostic and prognostic potential of tensin-2 (TNS2) levels in patients with breast cancer (BC). Methods: The study included sixty patients with BC and twenty healthy female controls for a comparative investigation of TNS2 protein and gene expression levels.. Results: Compared to the healthy controls, we found that the patient group showed a statistically significantly lower mean level of TNS2 protein (p<0.001) and higher mean level of TNS2 gene expression (p=0.015). Secondly, we examined the clinical utility of TNS2 levels as an indicator of invasiveness and aggressiveness in BC by comparing patient TNS2 levels by stage and grade. Although the measured mean values differed between the patients subgrouped by tumor biology, grade, and stage, we found that the differences were not statistically significant. Conclusion: Our findings suggest that TNS2 levels can be utilized diagnostically and prognostically, and that there is a need for further studies with larger he mean values measured differed between the patient subgroups based on tumor elucidate the clinical value of TNS2 protein and gene expression levels as an early prognosticator of aggressiveness in BC and thus a useful criterion in treatment optimization.Öğe The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer(MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, 2019) Üçüncü, Muhammed Zübeyr; Serilmez, Murat; Sarı, Murat; Bademler, Süleyman; Karabulut, SenemIn this study, we compared the levels of C-C chemokine receptor type 5 (CCR5), C-C motif chemokine ligand 5 (CCL5), platelet-derived growth factor (PDGF), and EphrinA7 (EphA7) in patients with colorectal carcinoma and healthy controls in order to investigate the significance and usability of these potential biomarkers in early diagnosis of colorectal cancer. The study included 70 colorectal carcinoma patients and 40 healthy individuals. The CCR5, CCL5, PDGF, and EphA7 levels were measured using ELISA in blood samples. PDGF-BB, EphA7, CCR5, and CCL5 levels of the patients with colorectal carcinoma were significantly higher compared to the control group (p < 0.001 for each comparison). Our logistic regression analysis (the area under the curve was 0.958) supports the notion that PDGF-BB, EphA7, and CCL5 are potential biomarkers for the diagnosis of colon cancer. The sensitivity, specificity, and positive and negative predictive values were found to be 87.9%, 87.5%, 92.1%, and 81.4%, respectively. To our knowledge, this is the first study that investigates the relationship between colorectal carcinoma and the four biomarkers CCL5, CCR5, PDGF, and EphA7. The significantly elevated levels of all these parameters in the patient group compared to the healthy controls indicate that they can be used for the early diagnosis of colorectal carcinoma.
